Pareto Optimized Adaptive Learning with Transposed Convolution for Image Fusion Alzheimer's Disease Classification.

Abstract

Alzheimer's disease (AD) is a neurological condition that gradually weakens the brain and impairs cognition and memory. Multimodal imaging techniques have become increasingly important in the diagnosis of AD because they can help monitor disease progression over time by providing a more complete picture of the changes in the brain that occur over time in AD. Medical image fusion is crucial in that it combines data from various image modalities into a single, better-understood output. The present study explores the feasibility of employing Pareto optimized deep learning methodologies to integrate Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) images through the utilization of pre-existing models, namely the Visual Geometry Group (VGG) 11, VGG16, and VGG19 architectures. Morphological operations are carried out on MRI and PET images using Analyze 14.0 software and after which PET images are manipulated for the desired angle of alignment with MRI image using GNU Image Manipulation Program (GIMP). To enhance the network's performance, transposed convolution layer is incorporated into the previously extracted feature maps before image fusion. This process generates feature maps and fusion weights that facilitate the fusion process. This investigation concerns the assessment of the efficacy of three VGG models in capturing significant features from the MRI and PET data. The hyperparameters of the models are tuned using Pareto optimization. The models' performance is evaluated on the ADNI dataset utilizing the Structure Similarity Index Method (SSIM), Peak Signal-to-Noise Ratio (PSNR), Mean-Square Error (MSE), and Entropy (E). Experimental results show that VGG19 outperforms VGG16 and VGG11 with an average of 0.668, 0.802, and 0.664 SSIM for CN, AD, and MCI stages from ADNI (MRI modality) respectively. Likewise, an average of 0.669, 0.815, and 0.660 SSIM for CN, AD, and MCI stages from ADNI (PET modality) respectively.